Teva Offers Drugs Valued at $23 Billion to End Opioid Suits - Bloomberg
Teva Hit With New Lawsuit Over Proposed Korlym Drug Copy
Teva Gets Fresh Cash, Fresh Woes | Ctech
Teva Sees Adderall Supply Delays Continuing for 2-3 Months (1)
With New Teva Deal, Combined NY Settlements With Opioid Makers Top $2 Billion | New York Law Journal
Teva Pharmaceuticals to pay New York $523 million to settle claims from its role in opioids crisis - ABC News
Teva Pharmaceuticals Names Kare Schultz As New CEO | Fortune
Teva CEO Vigodman steps down as drugmaker seeks direction | The Times of Israel
Israeli Drugmaker Teva in Talks to Help Produce Covid-19 Vaccines
Teva Is Facing Adderall Supply Disruptions as Demand for ADHD Drug Soars - Bloomberg
Teva Considering Cutting up to 10,000 Jobs: Bloomberg
Teva Pharmaceutical to Replace CEO Kare Schultz - WSJ
Teva Pharmaceuticals Could Face Billions in Damages From Opioid Lawsuits | Barron's
Teva to Sell Record $5 Billion of Sustainability-Linked Bonds - Bloomberg
Teva's Trouble Was Predicted. Path to Recovery Not as Clear - Bloomberg
Ex-Teva Chairman, Blockchain Investor Accused of Pump-and-Dump Scheme - WSJ
Teva CEO Calls 'Trough' Revenues Consequence of Patent Expirations - YouTube
Teva to Sell Record $5 Billion of Sustainability-Linked Bonds - Bloomberg
Teva Pharmaceutical Will Pay Over $4 Billion in Opioid Settlement - Bloomberg
Teva CEO Resigns; Dividend Cut Should Be Next - Bloomberg
Teva's Adderall Shortage Seen Continuing Into March (TEVA) - Bloomberg
Teva Cites 'Havoc' as It Takes Drug Label Spat to Supreme Court (1)
Teva CEO Kare Schultz Says Drugmaker Will Fight US Price-Fixing Charges - Bloomberg
Teva: Now What? | Barron's
252 Teva Pharmaceuticals Photos and Premium High Res Pictures - Getty Images
